Literature DB >> 3572434

Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.

J L Juncos, G Fabbrini, M M Mouradian, C Serrati, A M Kask, T N Chase.   

Abstract

A controlled release preparation of levodopa-carbidopa, CR III, given every 4 hours to 17 Parkinsonian patients for up to 10 months reduced plasma drug variations and improved motor response fluctuations compared with standard levodopa-carbidopa given every 2 hours. The results support the value of pharmaceutical approaches to the stabilisation of circulating levodopa levels in the treatment of Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3572434      PMCID： PMC1031491          DOI： 10.1136/jnnp.50.2.194

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  14 in total

1.  RADIOLOGICAL ABNORMALITIES OF THE UPPER PART OF THE ALIMENTARY TRACT IN PARKINSONISM.

Authors:  M J EADIE; J H TYRER
Journal:  Australas Ann Med       Date:  1965-02

2.  Sustained-release levodopa.

Authors:  A C Woods; G A Glaubiger; T N Chase
Journal:  Lancet       Date:  1973-06-16       Impact factor: 79.321

3.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

4.  On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.

Authors:  I Shoulson; G A Glaubiger; T N Chase
Journal:  Neurology       Date:  1975-12       Impact factor: 9.910

5.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

Authors:  J G Nutt; W R Woodward; J P Hammerstad; J H Carter; J L Anderson
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

6.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.

Authors:  J T Hutton; R L Dippel; J R Bianchine; H K Strahlendorf; P G Meyer
Journal:  Clin Neuropharmacol       Date:  1984       Impact factor: 1.592

9.  Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.

Authors:  R P Lesser; S Fahn; S R Snider; L J Cote; W P Isgreen; R E Barrett
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

10.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321
View more
  2 in total

Review 1.  Soluble and controlled-release preparations of levodopa: do we really need them?

Authors:  Giovanni Fabbrini; Flavio Di Stasio; Maria Bloise; Alfredo Berardelli
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

2.  Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.

Authors:  R J Coleman; N P Quinn; M Traub; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.